key: cord-0979698-arcqosj5
authors: Lin, Hui-Tsu; Chen, Cheng-cheung; Chiao, Der-Jiang; Chang, Tein-Yao; Chen, Xin-an; Young, Jenn-jong; Kuo, Szu-Cheng
title: Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice
date: 2021-11-11
journal: Int J Biol Macromol
DOI: 10.1016/j.ijbiomac.2021.11.020
sha: c785fff6b23a39d9fe3b19d46817cdbcdc630f5f
doc_id: 979698
cord_uid: arcqosj5

The spike (S) protein is a leading vaccine candidate against SARS-CoV-2 infection. The S1 domain of S protein, which contains a critical receptor-binding domain (RBD) antigen, potentially induces protective immunoreactivities against SARS-CoV-2. In this study, we presented preclinical evaluations of a novel insect cell-derived SARS-CoV-2 recombinant S1 (rS1) protein as a potent COVID-19 vaccine candidate. The native antigenicity of rS1 was characterized by enzyme-linked immunosorbent assay with a neutralizing monoclonal antibody targeting the RBD antigen. To improve its immunogenicity, rS1-adjuvanted with fucoidan/trimethylchitosan nanoparticles (FUC-TMC NPs) and cytosine-phosphate-guanosine-oligodeoxynucleotides (CpG-ODNs) were investigated using a mouse model. The S1-specific immunoglobulin G (IgG) titers, FluoroSpot assay, pseudovirus- and prototype SARS-CoV-2-based neutralization assays were assessed. The results showed that the rS1/CpG/ FUC-TMC NPs (rS1/CpG/NPs) formulation induced a broad-spectrum IgG response with potent, long-lasting, and cross-protective neutralizing activity against the emerging SARS-CoV-2 variant of concern, along with a Th1-biased cellular response. Thus, the rS1/CpG/NPs formulation presents a promising vaccination approach against COVID-19.

nanomaterials, have been employed as efficient nanocarriers for CpG ODN delivery [21] .

Nanocarriers have contributed to improving the safety and efficacy of SARS-CoV-2 vaccines [22, 23] .

Polysaccharide NPs from natural or synthetic biodegradable polysaccharides have been extensively used as vaccine adjuvants because of their biocompatibility and affordability. Positively or negatively surface-charged polysaccharide NPs can be easily prepared using a polyelectrolyte complexation (PEC) method with an anionic polyelectrolyte and a cationic polyelectrolyte through an environment-friendly process [24, 25] . Fucoidan (FUC) refers to a family of anionic fucose-containing sulfated polysaccharides extracted from marine brown algae [26] . FUC exhibits anticoagulant, antithrombotic, antiviral, antioxidant, anti-inflammatory, antitumor, anticomplementary, and immunomodulating properties. Previous experimental data also proved that FUC are agonists of innate immune receptors and strong inducers of cellular and humoral immune responses [27] . Cationic chitosan (CS) and its quaternary derivatives, such as trimethylchitosan (TMC) and N- (2-hydroxy-3-trimethylammonium) propyl-chitosan (HTCC), have various advantages as vaccine adjuvants that enhance both humoral and cellular immune responses after vaccination [28] . In addition, a CS-based adjuvant yielded better antigen-specific antibody titers and splenic CD4+ proliferation than an incomplete Freund's or an aluminum hydroxide adjuvant [29] .

CS-based NPs have been employed as nanocarriers and/or adjuvants for delivering several antigens 7 A recombinant baculovirus contains the hr1pag1 promoter that drives an insect codon-optimized synthetic gene encoding a fusion protein comprising of mosquito cecropin B1 signal peptide (1 st -24 th amino acid residues, sequence ID: KJ439044.1) and SARS-CoV-2 S1 (22-1216 th Arg319-Asn532 amino acid residues of S protein, Sequence ID: MT459919.1). C-terminally fused with enterokinase cut site-V5 epitope-8xHis. A total of 10 7 C6/36 cells were seeded into T-75 flasks (corning) and incubated for 16-18 h (Spectrums). The resultant product was subjected to affinity purification using TALON metal affinity resin (TAKARA).

To generate rabbit anti-SARS-CoV-2 RBD serum, a cDNA fragment of RBD from SARS-CoV-2 prototype was subcloned into pET32c plasmid. The expression, purification, and animal immunization of recombinant SARS-CoV-2 RBD were performed in accordance with methods described in a previous report [35] . Samples were resuspended in sample buffer, boiled, and loaded onto a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel. Following 8 ECL substrate and signals were captured using the Amersham Image 600 (GE Healthcare).

TMC was synthesized from chitosan via a two-step methylation procedure as described previously [25] . Positively charged FUC-TMC NPs were prepared using the PEC method, as previously reported [34] . Briefly, the FUC solution (4 mg/mL) was added dropwise into the TMC solution (4 mg/mL) at a mass ratio (FUC/TMC) of 0.6, and then stirred at 28 °C for 5 min. The particle size was characterized by photon correlation spectroscopy (Zetasizer Nano-ZS; Malvern Instruments, UK). All measurements were performed at a wavelength of 633 nm at 28 °C with a detection angle of 173 o . The raw data were correlated to the mean hydrodynamic size by cumulant analysis (Z-average mean). The zeta potentials of all NPs were analyzed via laser Doppler velocimetry (Zetasizer Nano-ZS; Malvern Instruments, UK). NP morphology was examined using a Hitachi HT-7700 transmission electron microscope (Minato-ku, Tokyo, Japan). TEM samples were prepared as follows: one drop of FUC-TMC NP suspension (resuspended in water from the pellet after centrifugation) was deposited on a 200-mesh Formvar/carbon-coated copper grid, and the excess solution was removed by wicking it with filter paper to avoid particle aggregation. Samples were stained with 2% phosphotungstic acid and dried at 28 °C.

2.6. Native antigenicity assay with an indirect enzyme-linked immunosorbent assay (ELISA) Further, 96-well plates were coated with purified rS1 or rS1 mixed with CpG ODN 1826 and FUC-TMC NPs with rS1 protein concentration of about 0.1 µg/well in carbonate-bicarbonate buffer overnight at 4 °C. Wells were blocked with 5% skim milk in PBS containing 0.05% Tween 20 (PBST) at 37 °C for 1 h. After blocking, 100 µL blocking buffer containing 0. 4, 4, 10, 25, 50, or 100 ng of either anti-SARS-CoV-2 S RBD neutralizing monoclonal antibody (NT mAb) (GTX01556, GeneTex) or control antibody (anti-Flavivirus mAb) was added to each well, followed by two washes with PBST. After an hour of incubation at 37 °C, four washes with PBST were performed, which was followed by incubation with peroxidase-labeled secondary antibody for 1 h at room temperature. Further, five washes with PBST were performed, followed by the addition of J o u r n a l P r e -p r o o f 9 100 µl/well TMB substrate for 10 min incubation at room temperature in the dark. TMB stop solution (50 µL) was added to each well, and the absorbance was read at 450 nm within 15 min.

Means of absorbance value calculated from 3 independent experiments in duplicate.

BALB/c mice were handled in strict accordance with regulations, as defined by the Council of Agriculture, Executive Yuan, Taiwan. The protocol was approved by the Institutional Animal Care and Use Committee of the Institute of Preventive Medicine, National Defense Medical Center . 35 female mice 8 weeks old (n = 5 per group) were intramuscularly (IM) immunized with either 1 μg rS1 protein alone or 5 μg rS1 protein alone or with 10 μg CpG or 10 μg CpG plus 200 μg FUC-TMC NPs at 8, 11, and 14 weeks of age. The negative control group received PBS CpG and FUC-TMC NPs. Blood was collected from all mice at 10, 13, and 16 weeks of age for the antibody assay. Additionally, blood from three mice of each rS1/CpG/NPs group was collected at seven months of age for a lasting neutralizing antibody assay. Three weeks after the final vaccination, splenocytes from one mice per group (median response of total IgG in the group) were isolated to conduct FluoroSpot assay.

The 96-well plates were coated with a commercial rS1 (HEK293-derived sheep Fc-Tagged rS1;

The Native Antigen, UK) at a concentration of 1 µg/ml in carbonate-bicarbonate buffer overnight at 4 °C. Wells were blocked with 5% skim milk in PBST at 37 °C for 1 h. Further, two washes with PBST were performed, followed by the addition of 100 µL of 100 to 1.56x10 6 -fold diluted sera (5-fold serial dilution) to each well and incubation at 37 °C for 1 h. Four washes with PBST were performed, followed by incubation with either peroxidase labelled anti-mouse IgG (KPL), IgG1 (Zymed), IgG2a (Invitrogen) or IgG2b (Bethyl) antibodies for 1 h at room temperature.

Furthermore, five washes with PBST were performed, followed by the addition of 100 µL TMB substrate/well for 10 min incubation at 28 °C in the dark. The TMB stop solution (50 µL) was added to stop the reaction. The optical density was measured at 450 nm within 15 min. (half maximal inhibitory dilution) of neutralizing antibody titer was calculated with GraphPad Prism as the reciprocal of the dilution: the sample showed that the RLUs were reduced by 50% as compared to pseudovirus-alone control wells.

Vero E6 cells were cultured in high-glucose DMEM (GeneDireX) supplemented with 10% (v/v) FBS in an incubator under a humidified atmosphere of 5% CO 2 at 37 °C. The viral titer of the SARS-CoV-2 strain 3586 (TSGH_15 GISAID accession number EPI_ISL_436100) that propagated in the Vero E6 cells was determined via plaque assays in the Vero E6 cells in the BSL-3 laboratory.

The Vero E6 cells (4×10 5 cells/well) were seeded into 12-well plates and incubated at 37 °C overnight. Pooled sera of mice and individual serum of SARS-CoV-2 patients inactivated at 56 °C for 30 min were first diluted (either 1/16 -1/625 or 1/16 -1/1562) in 2.5-fold DMEM medium.

Serially diluted serum (250 μL) was incubated with an equal volume of medium containing approximately 100 PFU of SARS-CoV-2. The mixtures were then added to VERO E6 cells and incubated at 37 °C for 1 h with occasional shaking. Cells were subsequently cultured in 4 ml DMEM containing 2% FBS and 1.55% (v/v) methylcellulose for 72 h. After culturing, the cells J o u r n a l P r e -p r o o f were fixed with 10% formaldehyde for 1 h at room temperature. Plaques were stained with 0.5% (w/v) crystal violet for at least 30 min at 28 °C and then counted. Nab titers were defined as the reciprocal of the maximum dilution of serum that reduced the virus titer by 50%. Two independent experiments were performed with very similar results, and the data presented represent the results from one independent experiment.

2.11. FluoroSpot assay Cellular immunity assay was performed using the Mouse IFN-γ/IL-4 FluoroSpot PLUS kit (Mabtech). Briefly, 5×10 5 splenocytes/well (in triplicate) in DMEM supplemented with 10% FBS and antibiotic-antimycotic was plated onto the precoated FluoroSpot plates. Further, the cells were incubated with either a peptide pool of SARS-CoV-2 S1 (Mabtech, 3629-1, Table S3 ) (5 μg/well), ConA (positive control, 2 μg/ml), or PBS (negative control) in RPMI 1640 medium at 37 °C for 48 h. Following incubation with monoclonal detection antibodies, secondary reagents conjugated to fluorophores, which is a fluorescence enhancer. Furthermore, positive cells were photographed and counted using an automated FluoroSpot reader equipped with filters for excitation 490 nm/emission 510 nm (LED490, FITC) for IFN-γ detection and excitation 550 nm/emission 570 nm (LED550, Cy3) for IL-4 detection.

Data were analyzed using the GraphPad Prism 6.01 software for statistically significant differences using a two-tailed, unpaired t test. Statistical significance was set at P < 0.05. The p-values are indicated as follows: ns: not significant; * p < 0.05: significant; ** p <0.01: highly significant.

In this study, the BacMos system was employed to produce a recombinant SARS-CoV-2 S1

protein for vaccine development. After harvesting from the four-day batch serum-free culture supernatants, the collected culture medium was clarified and subsequently concentrated by TFF.

J o u r n a l P r e -p r o o f 12 Further, the crude material was purified using the TFF-Co 2+ protocol. Western blot analysis (Fig. 1A) of the corresponding fractions confirmed that a protein of approximately 100 kDa molecular weight was present in the major band of the elution fraction using Coomassie blue staining (Fig. 1B) .

Furthermore, LC-MS/MS analysis revealed that this 100 kDa protein had a matching amino acid sequence of SARS-CoV-2 S1 protein with 59.41% coverage (Fig. 1C ). 

The formulation of SARS-CoV-2 rS1 used for immunization was developed by simply mixing the buffered solution of rS1, CpG, and FUC-TMC NPs. Nanosized FUC-TMC NPs with positive surface charges can be prepared via the PEC method, and the particle size and zeta potential of NPs depend on the mass ratio of anionic FUC to cationic TMC. rS1 and CpG are anionic; thus, the mass ratio of FUC/TMC must be carefully adjusted to avoid aggregation after mixing and to keep the surface positively charged. In this study, the mass ratio of FUC/TMC used to prepare NPs was 0.6, and the degree of quaternization of TMC was 52%. The particle sizes, polydispersity index (PDI), and zeta potentials of FUC-TMC NPs before and after mixing with rS1 and CpG are listed in Table   S1 . Fig. 2 shows the representative TEM images of FUC-TMC NPs and rS1/CpG/NPs. The TEM images of rS1/CpG/NPs (Figs. 2B-2D) showed much smaller particle sizes than the original J o u r n a l P r e -p r o o f 14 FUC-TMC NPs ( Fig. 2A) , and the particles loosely joined together to form agglomerates. Thus, the average particle size of rS1/CpG/NPs measured by Dynamic Light Scattering (DLS) was larger than that of the original FUC-TMC NPs (Table S1 ). This phenomenon may result from the anionic nature of rS1 and CpG. Furthermore, the addition of rS1 and CpG to FUC-TMC NPs changes the anion-to-cation ratio, and the particle rearranges to becomes smaller because PEC is a reversible process [33, 34] . Moreover, anionic rS1 and CpG can join more than one FUC-TMC NP via electrostatic interaction; thus, agglomerates were formed. A similar phenomenon was observed in our previous studies when polysaccharide NPs were mixed with anthrax vaccine adsorbed proteins [34] . 

To determine if rS1 possesses a native RBD conformation before and after mixing with CpG/NPs, J o u r n a l P r e -p r o o f the purified rS1 alone or rS1/CpG/NPs mixture was subjected to an indirect ELISA with an anti-SARS-CoV-2 S RBD neutralizing mAb. The results (Fig. 3) show that this neutralizing mAb exhibits dose-dependent binding to rS1 alone and rS1/CpG/NPs. Binding of mAb to rS1 alone at a concentration of 25 ng mAb/well or higher approaches saturation. Notably, the binding avidity of this neutralizing mAb on rS1/CpG/NPs was significantly higher than that of rS1 alone. These results suggested that rS1 maintained a native RBD structure in the rS1/CpG/NPs formulation as a vaccine candidate for SARS-CoV-2. 

To evaluate the immunogenicity of rS1, BALB/c mice were immunized with rS1, rS1/CpG, or rS1/CpG/NPs at week 0 (prime), week 2 (second injection), and week 8 (third injection). ELISA assay results (Fig. 4) showed that mice immunized with rS1/CpG/NPs induced S1 protein-specific total IgG, IgG1, IgG2a, and IgG2b antibodies at significantly higher levels after two doses of inoculation and extremely high levels after three doses of inoculation (Fig. 4B) . Notably, weak

IgG2a and IgG2b responses were observed in the rS1 alone group. Conversely, dominant IgG1, J o u r n a l P r e -p r o o f IgG2a, and IgG2b responses were detected in the rS1/CpG/NPs groups. Interestingly, mice group of 5 µg rS1/CpG/NPs perform significant higher titers of total IgG, IgG2a and IgG2b subtypes (cellular immunity) after second boost. Stratified ratios of Th1 (IgG2a) vs. Th2 (IgG1) subclasses ( Fig. 4C) , and stratified results confirmed that a trend toward an IgG2a bias and a more balanced response for the 5 μg rS1/CpG/NPs formulation. To detect neutralizing antibody titers, an individual serum was measured by the WT S-pseudovirus-based neutralization assay (Fig. 5A ) and compared with patient sera. After two doses of inoculation, the average ID50 titer (100 and 600) of rS1/CpG/NPs-immunized mice were significantly higher than the average ID50 titer (10 and 20) of rS1 alone. The average ID50 titer (600) of 5 μg rS1/CpG/NPs-immunized mice was higher than the average ID50 titer (250) of patient sera. After three doses of inoculation, the average ID50 titers (2500, 5000, 4000, 2000, and 10000) of all rS1-containing groups except the 1 μg group were significantly higher than the average ID50 titer (250) of patient sera.

To confirm neutralizing antibody titers, pooled sera were subjected to WT SARS-CoV-2-based neutralization assay (Fig. 5B ). Corresponding to the results of ID50 titers, the average PRNT50 titer (60) of 5 μg rS1/CpG/NPs-immunized mice were higher than the average PRNT50 titer (50) Beta-S or Delta-S pseudoviruses were measured (Fig. 5C ). Inoculation of rS1/CpG/NPs induced substantial neutralizing titers against D614G, Alpha-, or Beta-S pseudoviruses. Inoculation of rS1/CpG/NPs induced neutralizing activities against D614G-, Alpha-, Beta-S or Delta-S pseudoviruses with comparable titers. As expected, titers (rS1/CpG/NPs) of neutralizing antibodies against WT S-pseudovirus were slightly higher than titers of neutralizing antibodies against D614Gand Alpha-S pseudoviruses, and significantly higher than Beta-S and Delta-S pseudoviruses.

However, NT potency remained against these variants. Consistently, neutralization activities against authentic SARS-CoV-2 were lower than those against pseudovirus but they retained potency (median ID50 of 1501 and 3942 at weeks 6 and 12, respectively) (Figs. 5A and 5B). The rS1/CpG/NPs vaccine, which induced a broadly neutralizing antibody response to four SARS-CoV-2 variants, could meet the needs of next-generation SARS-CoV-2 vaccines (Table 1) .

To investigate the duration of neutralizing titers induced by rS1/CpG/NPs, sera collected 0.5 and 5 months after the final boost were subjected to WT S-pseudovirus-based neutralization assay (Fig.   5D ). The 1 μg dose of rS1/CpG/NPs remains an average ID50 titres of 4000 (range: 2500-5000) of 5 months as compared to an average ID50 titres of 7000 (range: 6000-7000) of 0.5 months, whereas 5 μg dose of rS1/CpG/NPs remains an average ID50 titres of 8000 (range: 5000-9000) of 5 months as compared to an average ID50 titres of 12000 (range: 6000-16000) of 0.5 months. This suggested that three doses of inoculation with rS1/CpG/NPs induced persistently high levels of neutralizing antibodies for at least 5 months in mice. Overall, these results suggest that the rS1/CpG/NPs formulation induces broadly durable NT activity against clinical SARS-CoV-2 variants.

To confirm Th polarity, splenocytes (1 mice/per group) were subjected to FluoroSpot assay for detection of IFN-γ-and IL-4-secreting cells (Fig. 6A) . We observed that splenocytes from mice immunized with rS1 alone presented a higher number of IL-4-secreting spots (310 and 340 spots/ 5×10 5 cells) than that of IFN-γ-secreting spots (110 and 150 spots/5×10 5 cells) upon peptide stimulation, thereby indicating the Th2-biased cellular responses in rS1 alone-immunized mice (Fig.   6B ). Conversely, the densities of IFN-γ-secreting spots (750 and 500 spots/5×10 5 cells) induced by rS1/CpG/NPs were higher than those of IL-4-secreting spots (180 and 90 spots/5×10 5 cells), thereby J o u r n a l P r e -p r o o f indicating the Th1-biased cellular responses in rS1/CpG/NPs-immunized mice. The 1 μg rS1/CpG/NPs dose maintained higher numbers of IFN-γ and IL-4-secreting spots than the 5 μg rS1/CpG/NPs dose, thereby suggesting that 1 μg rS1 dose is sufficient for a robust Th1-focused T cell response in CpG/NPs formulation. A higher background signal of IL-4 (90 and 120 spots/5×10 5 cells, without stimulation) was obtained following immunization with rS1 alone. However, rS1

adjuvanted with either CpG/NPs ( respectively. The data are presented as mean ± SEM, and the statistical significance between the groups under peptide stimulation was analyzed using Student's t-test (* p < 0.05). (C) Stratified SFC ratios of IFN-γ (Th1) vs. IL-4 (Th2).

Different successful vaccines are required to overcome the global SARS-CoV-2 pandemic.

Several vaccine strategies, such as using nucleic acid, viral vector, inactivated virus, and recombinant protein-based vaccines have been deployed, and some are under clinical use [36] .

Regarding safety, subunit vaccines containing specific viral protein fragments eliminate the concerns of incomplete viral inactivation, virulence revertant, and pre-existing immunity against viral vectors. The S protein of SARS-CoV-2 is an important target for neutralizing antibodies. A S trimer induced high levels of neutralizing antibodies and Th1-biased cellular immune responses in rodents and protected nonhuman primates from the SARS-CoV-2 challenge [37] . Additionally, the neutralizing epitope-rich S1 protein has been proven as an alternative target for effective and safe betacoronavirus vaccines [11] [12] [13] [14] . However, subunit vaccines need to be combined with adjuvant(s)

to improve immunogenicity and efficacy [38] .

Control of immune systems via TLR9 by CpG ODNs has proven to be effective in preventing J o u r n a l P r e -p r o o f infectious diseases, cancers, and allergies. However, ODNs with only a phosphodiester backbone are easily degraded by deoxyribonuclease. Thus, CpG ODNs with a phosphorothioate backbone, such as ODN 1826, have been studied for the placement of phosphodiesters for clinical application;

however, it has raised concerns regarding unfavorable side effects [39] . The advantages of using NPs as CpG ODN carriers include protection from DNase degradation, extension of retention time inside the body, improvement of cellular uptake efficiency, and delivery to target tissues.

Furthermore, NPs allow the slow release of CpG ODNs over a long period of time and change localization inside the body, thereby reducing the frequency of vaccinations and the dose of vaccines. As described previously, CpG ODNs do not require encapsulation in NPs to be protected from DNase activity; adsorption to NPs is sufficient [40] . Thus, using NPs is a quick approach to develop an efficient delivery system for CpG ODNs. Generally, the method of attaching CpG

ODNs by modifying negatively charged NPs with polycations is the most effective method [41] .

However, polycations elicit nonspecific adsorption of negatively charged molecules and usually promote the formation of NP aggregates. Moreover, the disadvantages of using NPs include an inability to establish the safety of NPs or clarify the metabolic process [39] . Various studies have been conducted to avoid these shortcomings of polycations using PEG [42] and polyanions.

Furthermore, it has been stated that ionizable cationic liposomes eliminate the disadvantages of polycations [43] . In this study, we used biodegradable FUC-TMC NPs as adjuvants and/or nanocarriers of rS1 and CpG ODN. Consequently, TMC and FUC exhibited some cytotoxicity and reduced viability of L929 cells, A549 cells, and JAWS II DCs. However, both positively and negatively charged FUC-TMC NPs were highly compatible with these cell lines and had low cytotoxicity (Table S2) . NP formation via PEC reduced the cytotoxicity and immunotoxicity of the original composites, thereby rendering FUC-TMC NPs safer than TMC and FUC as drug carriers or vaccine adjuvants [33, 34] . This phenomenon is likely a result of materials with stronger cationic or anionic charges producing higher cytotoxicity in cells and both FUC-TMC NPs with milder surface charge being caused by the complexation of cationic and anionic groups, thereby resulting in less J o u r n a l P r e -p r o o f toxicity than the original composites. In addition, rS1 protein and CpG ODN were more easily adsorbed on the surface of positively charged FUC-TMC NPs through electrostatic attraction, and only formed some agglomerates (Figs. 2B-2D). No aggregation was observed during formulation.

Here, the immunogenicity of rS1 alone or CpG-adjuvanted rS1 with or without the nanocarrier FUC-TMC NPs was investigated. Similar levels of IgG1/IgG2a and IgG1/IgG2b indicated that a balanced immune response was induced in the rS1/CpG/NPs groups (Fig. 4) . CpG/NPs modulated the humoral response towards Th1-type relative to both groups of rS1 alone and rS1/CpG, as indicated by the significant higher levels of IgG2a and IgG2b. Variants of Concern (VOCs), such as B.1.1.7, 501Y.V2, and P.1 lineages, have emerged [44] . Some of these mutants within the S protein are resistant to the neutralizing activities of NTD-and RBD-specific mAbs, convalescent sera, RNA-based, and protein-based vaccines-elicited sera [45] [46] [47] [48] [49] . This raises a global concern about the efficacies of the current Wuhan-Hu-1-based vaccines, which highlights the necessity of a strategy to elicit a broadly neutralizing antibody response against SARS-CoV-2 variants. The Wuhan-Hu-1 rS1 protein, which contains major neutralizing epitopes, potentially induces cross-neutralizing antibodies against clinical variants. The results ( Fig. 5A and Table 1 ) of the pseudovirus NT assay showed VOC D614G, B.1.1.7 (Alpha), and 501Y.V2 (Beta) that resulted in a 2-to-8-fold reduction and a slight but significant decrease compared to WT-S in neutralization by sera from S1/FUC-TMC NP-vaccinated mice. However, rS1/CpG/NPs-elicited mice sera retained potent cross-protective activity against the four clinical SARS-CoV-2 variants in the pseudovirus NT assay ( Fig. 5A and C). In line with previous findings, vaccine-elicited sera maintain high NT effectivity against the Alpha lineage but less than 50% NT effectivity against the Beta lineage [46, 47, 50] . [51] [52] [53] [54] . The Beta lineage, which contains 10 amino acid substitutions on S glycoprotein (vs. prototype) and rapidly emerged in South Africa in late 2020, is resistant to convalescent (prototype infection) and vaccinated sera [49] . The D614G mutation J o u r n a l P r e -p r o o f pseudovirus slightly reduced the sensitivity of the virus to serum neutralizing antibodies in individual convalescent COVID-19 patients [55] . Notably, the pseudotyped NT response against Wuhan-Hu-1 SARS-CoV-2 was sustained for up to five months (Fig. 5D ). This indicates that the rS1/CpG/NPs formulation could yield a broadly durable neutralizing repertoire and reduce the likelihood of the variant escaping host immunity. Overall, the rS1/CpG/NPs formulation exhibited the most potent neutralizing antibody and Th1 cellular immune responses. The median titer of ID50 in the group of 5 μg rS1/CpG/NPs after two doses of immunization was three times higher than the median titers of neutralizing antibodies in cohorts of six convalescent humans after recovery from SARS-CoV-2 infection (Fig. 5A ). rS1/CpG/NPs-based vaccines can induce a robust Th1-prone cellular immune response ( Fig. 4C and 6) . Importantly, the Th1 response may reduce ADE and activate both arms of the immune system [56] . The results (Fig. 6 ) revealed that rS1 alone induces a predominantly Th2 type response in mice. In contrast, CpG/FUC-TMC NPs-based formulated with rS1 elicit more potent neutralizing antibodies while boosting Th1 responses, which may improve vaccine safety, efficacy, and durability. We also conducted immunogenicity assays of rS1/FUC-TMC NPs in mice (data not shown); however, the results showed lower titers of S-specific IgG and NT responses in rS1/FUC-TMC NP formulation. This indicates that CpG plus FUC-TMC NPs are required to maximize the immunogenicity of rS1 in mice. Immunization with SARS and MERS coronavirus vaccines leads to pulmonary immunopathology on virus challenge [57] [58] [59] . A similar phenomenon has also been reported in clinical trials with whole-inactivated virus vaccines against RSV and measles virus [60, 61] . In addition, the importance of Th1 cell responses has been highlighted in a recent study of asymptomatic and mild SARS-CoV-2 convalescent samples [62] . These results emphasize that vaccines capable of generating Th1-dominant responses are important for providing protection against SARS-CoV-2. T cells play an important role in SARS-CoV-2 infection. Along this line, rS1/CpG/NPs vaccine candidate induced a robust SARS-CoV-2 S-specific Th1 response, which involves a higher cytotoxicity of CD8+ T cells to eliminate virus-infected cells and induction of CD4+ T cells to facilitate humoral responses [9, 63] .

J o u r n a l P r e -p r o o f Two doses of rS1/CpG/NPs formulation induced substantial neutralizing titers against the prototype and the D614G mutant of SARS-CoV-2 in mice. Furthermore, we confirmed the production of Th1-biased cellular responses in mice. This study is an important step toward the development of an efficacious vaccine for humans.

Immunization of two mammalian cell-derived rS1 can elicit high levels of neutralizing antibodies in various animals [64, 65] . In this study, we identify BacMos to be a potential clinically relevant platform for the production of rS1 protein as a vaccine immunogen. We formulated this rS1

with CpG/NPs, which induced a strong, broad, and durable neutralizing antibody response.

Currently, animal experiments in hamster and human ACE2-transgenic mice are ongoing to evaluate if FUC-TMC NPs-adjuvanted SARS-CoV-2 S1 protein vaccine can protect against SARS-CoV-2 infection.

In this study, we verified that FUC-TMC NPs are good nanocarriers and adjuvant candidates for intramuscularly administered CpG ODN-adjuvanted SARS-CoV-2 rS1 protein vaccine. In vitro studies suggested that rS1 maintained correct folding in the formulation of rS1/CpG/NPs. Furthermore, FUC-TMC NPs are easily produced on a large scale via a simple mixing process of two oppositely charged polyelectrolytes; thus, they are more cost effective than chemically synthesized adjuvants, such as CpG ODNs. In the murine model, rS1 the CpG/NPs formulation induced a broad-spectrum IgG response, improved longevity and breadth of NT activity, and Th1-biased cellular responses. In summary, in this study, we suggest that rS1/CpG/NPs formulation is a promising COVID-19 vaccine candidate.

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Distinct conformational states of SARS-CoV-2 spike protein

Molecular Architecture of the SARS-CoV-2 Virus

Potently neutralizing and protective human antibodies against SARS-CoV-2

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen

Evaluation of candidate vaccine approaches for MERS-CoV

Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid J o u r n a l P r e -p r o o f translational development

Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop

Protein N-glycosylation in the baculovirus-insect cell system

Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice

Baculovirus as an efficient vector for gene delivery into mosquitoes

Mosquito Cell-Derived Japanese Encephalitis Virus-Like Particles Induce Specific Humoral and Cellular Immune Responses in Mice

Nanodelivery systems for enhancing the immunostimulatory effect of CpG oligodeoxynucleotides

Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape

Nanocarrier vaccines for SARS-CoV-2

Novel protein-loaded chondroitin sulfate-N

propyl]chitosan nanoparticles with reverse zeta potential: preparation, characterization, and ex vivo assessment

Positively and negatively surface-charged chondroitin sulfate-trimethylchitosan nanoparticles as protein carriers

The sulfated polysaccharides of brown algae and products of their enzymatic transformation as potential vaccine adjuvants

Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in Mice

Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination

Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax

Enteric trimethyl chitosan nanoparticles containing hepatitis B surface antigen for oral delivery

A step-by-step approach to study the influence of N-acetylation on the adjuvanticity of N,N,N-trimethyl chitosan (TMC) in an intranasal nanoparticulate influenza virus vaccine

A fucoidan-quaternary chitosan nanoparticle adjuvant for anthrax vaccine as an alternative to

CpG oligodeoxynucleotides

Nanoparticles assembled from fucoidan and trimethylchitosan as anthrax vaccine adjuvant: In vitro and in vivo efficacy in comparison to CpG

Cell-based analysis of Chikungunya virus membrane fusion using baculovirus-expression vectors

Immunological considerations for COVID-19 vaccine strategies

COVID-19 subunit vaccine candidate

Advancements in the development of subunit influenza vaccines

Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system

Design of mesoporous silica/cytosine-phosphodiester-guanin oligodeoxynucleotide complexes to enhance delivery efficiency

Polymeric materials for gene delivery and DNA vaccination

Design and development of polymers for gene delivery

Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy

Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England

Nussenzweig, mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Novavax offers first evidence that COVID vaccines protect people against variants

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Vaccines against the B.1.617.2 (Delta) Variant

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity and decreases neutralization sensitivity to individual convalescent sera, bioRxiv (2020) preprint

Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses

Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus

A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge

Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

Altered reactivity to measles virus

Atypical measles in children previously immunized with inactivated measles virus vaccines

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates

CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization

Lin: Investigation, Formal analysis, Data Curation

Conceptualization, Methodology, Funding acquisition, Supervision, Resources

Chiao: Investigation, Formal analysis, Data Curation

Formal analysis, Data Curation, Resources. Xin-an Chen: Investigation, Formal analysis, Validation

Writing -Original Draft, Review & Editing, Project administration, Funding acquisition

Writing -Original Draft, Review & Editing, Project administration, Funding acquisition